

Contents

1. Cardiovascular Pharmacology 1

1.1 Diuretics 1

Introduction 1

Classification of the diuretic compounds 1

Clinical pharmacology of the diuretic compounds 2

Adaptive responses to diuretic administration 4

Individual diuretic classes 5

Clinical use of diuretics in cardiovascular diseases 11

Adverse effects of diuretics 15

1.2 Vasodilators and Neurohormone Modulators 18

Introduction 18

Vasodilator drugs and low blood pressure 19

Arteriolar vasodilators 19

Renin–angiotensin–aldosterone system (RAAS) blockers 22

Mineralocorticoid (aldosterone) receptor blockers 26

Phosphodiesterase type 5 inhibitors 28

Intravenous vasodilators 28

Oral β -adrenergic blocking drugs 29

1.3 Positive Inotropic Drugs 32

Introduction 32

Intravenously administered, short-term

positive inotropic therapy 32

1.4 Antilipid Agents 41

Introduction 41

Appropriate uses 42

Statins 43

Add-on to statin therapy 50

Bile acid sequestrants 50

Ezetimibe 51

Niacin 51

Triglyceride-lowering therapy 52

Fibrates 52

Omega-3 fatty acids 53

Drugs in development 54

1.5 Antithrombotic and Antiplatelet Agents 54

Introduction 54

Clotting, A primer 55

Antithrombotic agents 55

Vitamin K antagonists (VKA) 58

Direct factor Xa inhibitors 59

Direct thrombin inhibitors 60

Antiplatelet agents 63

2. Diagnosis**70****2.1 History and Physical Examination 70***History 70**Physical examination 75***2.2 Plain Film Imaging of Adult Cardiovascular Disease 90***Introduction 90**Chest film technique 90**Cardiac anatomy on chest radiographs 91**Cardiac chamber enlargement 92**Radiographic manifestations of congestive heart failure 96**Cardiac calcifications 98**Acquired valvular heart disease 98**Pericardial disorders 100***2.3 Electrocardiogram 101***Introduction 101**Basis of electrocardiography 101**Component parts of the electrocardiogram 102**Lead systems used to record the electrocardiogram 102**A systematic way of looking at the interpretation of the electrocardiogram 103**Characterization of QRS complex 108**ST-T wave abnormalities 112**"U" wave 113**QT interval 113***2.4 ECG Exercise Testing 115***Introduction 115**Before the test 115**Methodology of exercise testing 117**During the test 119**After the test 126**Screening 128***2.5 Left Ventricle 132***Introduction 132**Systolic function 132**Contrast-enhanced echocardiography 134**Other echo-derived indices of left ventricular systolic function 134**Strain-derived indices 135**Recognizing the etiology of cardiac dysfunction 135**Visual qualitative indicators of systolic dysfunction 135**Diastolic function 136***2.6 Transthoracic Echocardiography 139***Introduction 139**Chamber quantitation 141**Doppler ECHO 143**Diastolic function 143**Pulmonary hypertension 144**Pericardial disease 144*

	<i>Valvular heart disease</i>	145
	<i>Infective endocarditis</i>	148
	<i>Intracardiac masses</i>	148
	<i>Contrast echocardiography</i>	149
	<i>Cardiac resynchronization therapy</i>	149
2.7	Stress Echocardiography	150
	<i>Introduction</i>	150
	<i>Using stress echocardiography in clinical decisions</i>	150
	<i>Future of stress ECHO</i>	155
2.8	Transesophageal Echocardiography	156
	<i>Introduction</i>	156
	<i>Performance</i>	156
	<i>Safety</i>	156
	<i>Views</i>	156
	<i>Major clinical applications</i>	158
	<i>Structural valve assessment</i>	161
	<i>Acute aortic dissection</i>	164
	<i>Procedural adjunct or intraoperative transesophageal echocardiography</i>	165
2.9	Cardiovascular Nuclear Medicine— Nuclear Cardiology	167
	<i>Introduction</i>	167
	<i>Myocardial perfusion imaging</i>	167
	<i>Positron emission tomography perfusion and metabolism</i>	169
	<i>Imaging myocardial viability</i>	169
	<i>Imaging perfusion</i>	171
	<i>Radiation concerns</i>	172
2.10	Cardiac Computed Tomography	173
	<i>Introduction</i>	173
	<i>Coronary artery disease</i>	173
	<i>Myocardium and chambers</i>	176
	<i>Pulmonary veins</i>	176
	<i>Cardiac veins</i>	177
	<i>Valvular disease</i>	177
	<i>Pericardium</i>	177
	<i>Future</i>	177
2.11	Cardiovascular Magnetic Resonance Imaging	178
	<i>Introduction</i>	178
	<i>Diagnosis of epicardial coronary artery stenosis</i>	178
	<i>Assessment of global and regional left ventricular function at rest and during inotropic stress</i>	179
	<i>Myocardial perfusion imaging</i>	179
	<i>Cardiovascular magnetic resonance coronary angiography</i>	180
	<i>Dilated cardiomyopathy</i>	181
	<i>Hypertrophic cardiomyopathy</i>	181
	<i>Restrictive cardiomyopathy</i>	181
	<i>Cardiovascular magnetic resonance-guided therapy</i>	182
	<i>Valvular heart disease</i>	182
	<i>Diseases with right ventricular predominance</i>	182
	<i>Miscellaneous conditions</i>	183

2.12 Molecular Imaging of Vascular Disease 184

Introduction 184

Molecular imaging modalities 184

Molecular imaging of vascular disease processes 186

2.13 Cardiac Hemodynamics and Coronary Physiology 190

Introduction 190

Cardiac catheterization—the basics 190

Cardiac cycle pressure waveforms 192

Hemodynamics in valvular heart disease 193

Hemodynamics in cardiomyopathy 197

Hemodynamics in pericardial disease 198

Coronary hemodynamics 200

2.14 Cardiac Biopsy 201

Introduction 201

Techniques 201

Safety and complications 202

Analysis of EMB tissue 203

Indications 204

2.15 Coronary Angiography and Catheter-based Coronary Intervention 207

Introduction 207

Indications for coronary angiography 207

Contraindications for coronary angiography 207

Patient preparation 209

Sites and techniques of vascular access 209

Catheters for coronary angiography 211

Arterial nomenclature and extent of disease 211

Angiographic projections 212

Congenital anomalies of the coronary circulation 213

General principles for coronary and/or graft cannulation 214

Fluoroscopic imaging system 214

Characteristics of contrast media 214

Access site hemostasis 215

Complications of cardiac catheterization 216

Percutaneous coronary intervention 217

Pharmacotherapy for PCI 221

Parenteral anticoagulant therapy 222

Percutaneous transluminal coronary angioplasty 222

Coronary stents 223

Types of stents 223

Procedural success and complications related to coronary intervention 223

3. Electrophysiology

226

3.1 Arrhythmia Mechanisms 226

Introduction 226

Arrhythmia initiation 226

3.2 Antiarrhythmic Drugs 234

Introduction 234

	<i>Arrhythmia mechanisms and antiarrhythmic drugs</i>	234
	<i>Indications for antiarrhythmic drug therapy</i>	234
	<i>Classification scheme</i>	235
	<i>Vaughan–Williams classification</i>	235
	<i>Antiarrhythmic drug selection in atrial fibrillation</i>	239
	<i>Outpatient versus in-hospital initiation for antiarrhythmic drug therapy</i>	240
	<i>Antiarrhythmic drugs in pregnancy and lactation</i>	241
	<i>Comparing antiarrhythmic drugs to implantable cardioverter defibrillators in patients at risk of arrhythmic death</i>	242
	<i>Antiarrhythmic drug–device interactions</i>	242
3.3	Syncope	243
	<i>Introduction</i>	243
	<i>Diagnostic tests</i>	245
	<i>Approach to the evaluation of syncope</i>	250
3.4	Atrial Fibrillation	253
	<i>Introduction</i>	253
	<i>Definition and Classification</i>	253
	<i>Etiology and Pathogenesis</i>	254
	<i>Diagnosis</i>	256
	<i>Management</i>	257
3.5	Supraventricular Tachycardia	261
	<i>Introduction</i>	261
	<i>Classification</i>	261
	<i>Diagnosis</i>	265
	<i>Treatments</i>	266
3.6	Clinical Spectrum of Ventricular Tachycardia	271
	<i>Introduction</i>	271
	<i>Monomorphic ventricular tachycardia</i>	272
3.7	Bradycardia and Heart Block	280
	<i>Introduction</i>	280
	<i>Bradycardia syndromes/diseases</i>	280
	<i>Clinical presentation</i>	281
	<i>Measurement/diagnosis</i>	281
	<i>Sinus node disease</i>	282
	<i>AV node disease</i>	282
	<i>Hemiblock</i>	283
	<i>Bundle branch block</i>	284
	<i>Treatment</i>	284
3.8	Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy	285
	<i>Introduction</i>	285
	<i>Molecular and genetic background</i>	285
	<i>Clinical presentation</i>	287
	<i>Clinical diagnosis</i>	288
	<i>Nonclassical ARVD/C subtypes</i>	289
	<i>Molecular genetic analysis</i>	289
	<i>Prognosis and therapy</i>	290

3.9 Long QT, Short QT, and Brugada Syndromes 291

Introduction 291
LQT syndrome 291
Brugada syndrome 294

3.10 Cardiac Resynchronization Therapy 296

Introduction 296
CRT: rationale for use 296
CRT in practice 296
Summary of CRT benefit 296
Prediction of response to CRT therapy 299
Role of dyssynchrony imaging 300
Dyssynchrony summary 300
CRT complications 300
Emerging CRT indications 300

3.11 Ambulatory Electrocardiographic Monitoring 305

Introduction 305
Holter monitoring 305
Event recorders 307
Mobile cardiac outpatient telemetry 308
Implantable loop recorders 308

3.12 Cardiac Arrest and Resuscitation 311

Introduction 311
Basic life support 312
Advanced cardiac life support 315
Risks 316
Cessation of resuscitation 318
Postresuscitation care 318

3.13 Risk Stratification for Sudden Cardiac Death 319

Introduction 319
Healthy athletes 319
Brugada syndrome 320
Long QT interval syndrome 320
Early repolarization 320
Short QT syndrome 320
Catecholamine polymorphic ventricular tachycardia 320
Wolff–Parkinson–White syndrome 321
Marfan's syndrome 321
Congenital heart disease 321
Nonischemic cardiomyopathy 322
Coronary artery disease 322

4. Coronary Heart Diseases

324

4.1 Coronary Heart Disease: Risk Factors 324

Introduction 324
CHD screening and prevention 325
Clustering and multiplicative effects of risk factors 325
CHD risk estimation 325
Traditional CHD risk factors 328
Emerging risk factors 332
Subclinical atherosclerosis 332

*Translating risk factor screening into event
reduction 332*

4.2 Acute Coronary Syndrome (Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction): Diagnosis and Early Treatment 333

Introduction 333
Unstable angina and non-ST-segment 333
Clinical features 333
*Risk stratification—putting it all together to determine
the optimal treatment strategy 336*
Early medical therapy 336
Early invasive or initial conservative strategy 340
Revascularization 341

4.3 Acute Coronary Syndrome II (ST-Elevation, Myocardial Infarction, and Post-Myocardial Infarction): Complications and Care 343

Introduction 343
Clinical presentation 343
Reperfusion 345
Early medical therapy 347
Postmyocardial infarction care 348
Complications 350
Special considerations 351
*Continued medical therapy for patients with
a myocardial infarction 351*

4.4 Management of Patients with Coronary Artery Disease and Stable Angina 354

Introduction 354
Current therapeutic approaches for stable angina 354
Antianginal drug therapy 354
Newer antianginal drugs 356
Combination therapy 357
Other drugs in patients with stable angina and chronic CAD 357
Role of myocardial revascularization 357
*Comparison of revascularization with pharmacological
antianginal therapy 358*

4.5 Cardiogenic Shock in Acute Coronary Syndromes 360

Introduction 360
Pathophysiology 360
Other cardiac causes of cardiogenic shock 361
Diagnostic evaluation 363
Medical management 363
Mechanical support 363
Revascularization 363

4.6 Acute Right Ventricular Infarction 364

Introduction 364
Patterns of coronary compromise resulting in RVI 364
Effects of ischemia on RV systolic and diastolic function 365
Effects of reperfusion on ischemic RV dysfunction 365
Rhythm disorders and reflexes associated with RVI 366

Clinical Presentations and Evaluation 366
Noninvasive and hemodynamic evaluation 367
Differential diagnosis of RVI 367
Therapy 367

5. Valvular Heart Diseases

369

5.1 Aortic Valve Disease 369

Aortic stenosis 369
Aortic regurgitation 374

5.2 Mitral Valve Disease 380

Introduction 380
Rheumatic heart disease 380
Mitral stenosis 381
Mitral regurgitation 388

5.3 Tricuspid Valve Disease: Evaluation and Management 397

Introduction 397
Etiology of tricuspid valve disease 397
Clinical presentation 398
Laboratory diagnosis 399
Treatment 400

5.4 Congenital Pulmonic Stenosis 403

Introduction 403
Valvar pulmonic stenosis 403
Isolated infundibular stenosis 408
Supravalvar stenosis 409

5.5 Catheter-based Treatment of Valvular Heart Disease 410

Introduction 410
Catheter-based treatment of mitral valve disease 410
Catheter-based treatment of pulmonary valve disease 413
Catheter-based therapies for aortic stenosis 414

5.6 Infective Endocarditis 417

Introduction 417
Pathogenesis 418
Presentation and diagnosis 422
Management 425

5.7 Prosthetic Heart Valves 433

Risk of valve replacement 433
Types of prosthetic valves 434
Selecting the optimal prosthesis 434
Prosthesis-patient mismatch 437
Long-term management 441
Long-term complications 444

5.8 Antithrombotic Therapy in Valvular Heart Disease 451

Introduction 451
Prophylactic antithrombotic therapy 452
Rheumatic valvular heart disease 453
Mitral valve prolapse 453
Calcified or degenerative valvular disease 453

Prosthetic valves 454
Bioprosthetic valves 454
Valvuloplasty and valve repair 455
Management issues 455

6. Vascular Diseases 458

6.1 Evaluation and Management of the Patient with Essential Hypertension 458

Evaluation of the patient with hypertension 458
Antihypertensive therapy 462
Hemodynamic concepts 463
Clinical pharmacologic concepts 463
Treatment algorithms advocated over the years 468

6.2 Peripheral Vascular and Cerebrovascular Disease 469

Introduction 469
Peripheral arterial disease 470
Carotid artery disease 477
Renal artery stenosis 479
Subclavian artery stenosis 480
Mesenteric ischemia 481

6.3 Aortic Dissection and Aneurysm 483

Aortic Dissection 483
Introduction 483
Classification 483
Clinical examination 484
Diagnosis 485
Treatment 487
Aortic Aneurysm 489
Introduction 489
Treatment 489
Anatomic substrate for endovascular aneurysm repair 490
Adjunctive devices and techniques 490
Endoleak 490
Late-occurring complications of endovascular aneurysm repair 491
Follow-up imaging 492

6.4 Autonomic Dysfunction and the Cardiovascular System 493

Introduction 493
Autonomic regulation of the cardiovascular system 493
Autonomic testing 495
Primary chronic autonomic failure 497
Secondary and congenital autonomic failure 498
Chronic orthostatic intolerance 498

7. Heart Failure 500

7.1 Diagnosis 500

Analysis of symptoms 500
Physical examination 501

Electrocardiogram 503
Chest radiograph 505
Echocardiography 505
Cardiac magnetic resonance and cardiac tomography 506
Biomarkers 507
Exercise tests and six-minute walk test 510
Myocardial ischemia 511
Genetic studies 512

7.2 Systolic Heart Failure (Heart Failure with Reduced Ejection Fraction) 513

Introduction 513
Ventricular remodeling 514
Functional derangements and hemodynamic consequences 519
Initial treatment of systolic heart failure 520
Symptomatic systolic heart failure 521
Nonpharmacologic treatments 524
Follow-up evaluation 525

7.3 Diastolic Heart Failure (Heart Failure with Preserved Ejection Fraction) 526

Definition 526
Epidemiology and risk factors 526
Pathophysiology 526
Future directions 532

7.4 Cardiorenal Syndrome: The Interplay between Cardiac and Renal Function in Patients with Congestive Heart Failure 534

Definition of the cardiorenal syndrome 534
*Role of evidence-based therapies in patients with
heart failure and the cardiorenal syndrome* 536
*Role of ultrafiltration on diuretic resistance and the cardiorenal
syndrome* 541
*Treatment of the cardiorenal syndrome:
an approach to the individual patient* 541

7.5 Acute Heart Failure Syndromes 545

Introduction 545
Pathophysiology 546
Acute heart failure syndromes management 548
Clinical trials in acute heart failure syndromes 556

7.6 Cardiopulmonary Exercise Testing and Training in Heart Failure 558

Introduction 558
Exercise response in heart failure 559
Cardiopulmonary exercise testing 560
Indications for CPX testing in heart failure 565
Exercise training in heart failure 566

7.7 Advanced Cardiac Therapies for End-stage Heart Failure: Cardiac Transplantation and Mechanical Circulatory Support 568

Introduction 568

<i>Identifying candidates for advanced cardiac therapies</i>	569
<i>Heart transplantation</i>	571
<i>Mechanical circulatory support</i>	581
<i>Future directions</i>	587

8. Myocardial and Pericardial Diseases **591**

8.1 Hypertrophic Cardiomyopathy 591

<i>Introduction</i>	591
<i>Pathology</i>	592
<i>Clinical presentation</i>	594
<i>Diagnosis</i>	595
<i>Natural history</i>	598
<i>Management</i>	599
<i>Dual-chamber pacemaker</i>	602

8.2 Dilated Cardiomyopathy 604

<i>Introduction</i>	604
<i>Definition</i>	604
<i>Pathology</i>	604
<i>Etiology</i>	605
<i>Prognosis</i>	608

8.3 Restrictive and Obliterative Cardiomyopathies 610

<i>Introduction</i>	610
<i>Restrictive cardiomyopathies</i>	610
<i>Tropical endomyocardial fibrosis (Davie's disease)</i>	612
<i>Right ventricular endomyocardial fibrosis</i>	612
<i>Left ventricular endomyocardial fibrosis</i>	613
<i>Loeffler's endocarditis</i>	614
<i>Idiopathic restrictive cardiomyopathy</i>	615

8.4 Specific Cardiomyopathies 616

<i>Amyloid Heart Disease</i>	616
<i>Introduction</i>	616
<i>Overview of cardiac amyloidosis</i>	616
<i>Classification of amyloidosis</i>	617
<i>Cardiac amyloidosis</i>	617
<i>Treatment</i>	621
<i>Peripartum Cardiomyopathy</i>	623
<i>Introduction</i>	623
<i>Diagnosis</i>	623
<i>Prognosis</i>	623
<i>Treatment</i>	624
<i>Labor and delivery</i>	624
<i>Chemotherapy-induced Cardiomyopathy</i>	625
<i>Introduction</i>	625
<i>Pathophysiology of anthracycline-induced cardiomyopathy</i>	625
<i>Mechanism of chemotherapy-induced cardiac dysfunction</i>	626
<i>Diagnosis</i>	627
<i>Monitoring</i>	628
<i>Preventive strategies</i>	629
<i>Treatment</i>	629

8.5 Pericardial Disease 631

Introduction 631

Acute pericarditis 631

Chronic relapsing pericarditis 633

Pericardial effusion and pericardial tamponade 634

Constrictive pericarditis 635

8.6 Radiation-induced Heart Disease 641

Introduction 641

Radiation-induced pericardial disease 641

Radiation-induced myocardial disease 642

Radiation-induced coronary artery disease 643

Radiation-induced valvular heart disease 643

Conduction system disease 644

Prevention 644

9. Pulmonary Vascular Disease and Adult Congenital Heart Disease

646

9.1 Pulmonary Arterial Hypertension 646

Definitions and classifications 646

Pathophysiology of pulmonary arterial hypertension 649

Diagnostic evaluation 651

Therapeutic options for the treatment of pulmonary arterial hypertension 657

Treatment algorithm and evaluating response to therapy 661

Therapy of decompensated right heart failure in pulmonary arterial hypertension 662

9.2 Congenital Heart Disease in the Adult Patient 665

Acyanotic Heart Disease 665

Congenital valvar aortic stenosis 665

Coarctation of the aorta 667

Valvar pulmonic stenosis 670

Atrial septal defects 672

Ventricular septal defects 674

Patent ductus arteriosus 677

Other Acyanotic Lesions 680

Ebstein's Anomaly 680

Cyanotic Congenital Heart Disease 682

Palliative shunts 683

Tetralogy of Fallot 683

Truncus arteriosus 690

Total anomalous pulmonary venous return 691

10. Secondary Disorders of the Heart

695

10.1 Alcohol and Arrhythmia 695

Direct effects of ethanol exposure on heart cells and tissues 695

Ethanol ingestion and the normal cardiac conduction system 695

- Binge drinking and transient clinical arrhythmias—
holiday heart* 695
- Alcohol consumption, chronic atrial fibrillation, and
atrial flutter* 696
- Alcohol consumption and sudden cardiac death* 696
- Summary and clinical guidelines* 697

10.2 Insulin Resistance and Cardiomyopathy 698

- Introduction* 698
- Diastolic heart failure and insulin resistance* 698
- Myocardial energy metabolism* 699
- Metabolic effects of insulin resistance* 700
- Structural effects of insulin resistance* 701
- Treatment* 702

10.3 Cardiac Complications of Substance Abuse 705

- Introduction* 705
- Substances of abuse* 705
- Marijuana, tetrahydrocannabinol, hashish* 710
- Club drugs: MDMA, GHB, ketamine, rohypnol* 710
- Body image drugs* 712
- Narcotics* 712

10.4 HIV/AIDS and Cardiovascular Disease 713

- Introduction* 713
- HIV and coronary heart disease* 714
- Surrogate measures of atherosclerosis* 716
- HIV-related left ventricular dysfunction and myocarditis* 717
- Cerebrovascular disease* 718
- Miscellaneous* 718

10.5 Systemic Autoimmune Diseases and the Heart 719

- Rheumatoid arthritis* 719
- Spondyloarthropathies* 721
- Polymyositis—dermatomyositis* 723
- Systemic lupus erythematosus* 724

10.6 Neurogenic and Stress Cardiomyopathy 726

- Introduction* 726
- Neurogenic cardiomyopathy* 726
- Stress cardiomyopathy* 729

10.7 Kidney and the Heart 732

- Introduction* 732
- Pathophysiology* 732
- Cardiovascular risk factors in chronic kidney disease* 733
- Spectrum of cardiovascular disease in
chronic kidney disease* 734
- Diagnostic tests* 736
- Principles of treatment of cardiovascular disease* 738
- Kidney transplant recipients* 738

10.8 Endocrine Heart Disease 740

- Introduction* 740
- Diabetes mellitus* 740
- Thyroid disease* 742

Pituitary disorders 744
Adrenal disorders 745
Parathyroid disorders 747
Carcinoid syndrome 747

10.9 Venous Thromboembolism and Cor Pulmonale 749

Venous thromboembolism 749
Cor pulmonale 758

11. Relevant Issues in Clinical Cardiology 761

11.1 Noncardiac Surgery in Cardiac Patients 761

Introduction 761
Preoperative cardiac risk assessment 761
Preoperative diagnostic testing 764
Preoperative risk mitigation strategies 766
Intraoperative management 768
*Management of patients with implanted
 electronic devices* 768
Postoperative management 768

11.2 Gender and Cardiovascular Disease 770

Introduction 770
Prevalence of IHD in women 770
Identification of IHD risk factors in women 770
*Assessment of symptoms and myocardial ischemia in
 women symptom assessment* 771
Management of IHD in women 774
Heart failure in women 777
Gender and cardiac arrhythmias 777

11.3 Overview of the Athlete's Heart 779

Introduction 779
Exercise physiology and the athlete's heart: overview 779
Issues relevant to the cardiovascular care of athletes 780

11.4 Cardiovascular Aging 783

Introduction 783
Age-related changes 784
Clinical syndromes 785
Special issues 788

12. Preventive Strategies for Other Cardiovascular Diseases 790

12.1 Prevention of Heart Failure 790

Introduction 790
Staging of heart failure 790
Future perspectives 794

12.2 Stroke: Prevention and Treatment 795

Introduction 795
Definitions 795
Stroke as a symptom 796
Prevention 804

General acute treatment 804
Treatment of acute ischemic stroke 805
Treatment of acute hemorrhagic stroke 807
General in-hospital care and rehabilitation 808

12.3 Rheumatic Fever 810

Introduction 810
Pathogenesis 810
Diagnosis of rheumatic fever 811
Clinical features 812
Treatment 814

13. Evolving Concepts 818

13.1 Preventing Errors in Cardiovascular Medicine 818

Introduction 818
Modern approach to patient safety 818
How to improve patient safety? 819
Communication and culture 820
Learning from mistakes 821
Creating a safe workforce 821
Preventing diagnostic errors 821
What can patients do to keep themselves safe? 822
Changing policy context for patient safety 822

13.2 Integrative Cardiology: The Use of Complementary Therapies and Beyond 823

Nonconventional therapies and cardiology 823
What is integrative medicine? 823
What is integrative cardiology? 823
Dyslipidemia 824
Hypertension 826
Coronary artery disease 828
Heart failure 830

Index 835